Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Lisa Licitra et al.|The Lancet|2018Cited by 1.7k
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.Jan B. Vermorken, Paul M. Clément, Frédéric Peyrade et al.|Journal of Clinical Oncology|2012Cited by 7